JUPITER, Fla., May 08, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and to develop and manufacture prophylactic, therapeutic, and nutritional biopharmaceutical products for human and animal health and wellness, today announced that its management will be attending the following industry and investor ev
JUPITER, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a biotechnology company focused on the efficient large-scale manufacture of proteins for use in human and animal vaccines and therapeutics, as well as in non-pharmaceutical applications including food, nutrition, and wellness, today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on
Dyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript March 28, 2024 Dyadic International, Inc. misses on earnings expectations. Reported EPS is $-0.08 EPS, expectations were $-0.07. DYAI isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good evening, and welcome […]